Loading…
Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study
This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes. We reviewed the baseline demographics, c...
Saved in:
Published in: | Frontiers in surgery 2023-03, Vol.10, p.1121357-1121357 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3 |
---|---|
cites | cdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3 |
container_end_page | 1121357 |
container_issue | |
container_start_page | 1121357 |
container_title | Frontiers in surgery |
container_volume | 10 |
creator | Bai, Xuesong Chen, Guo Shang, Shihai Li, Senlin Liu, Huanrui Feng, Zhenwei Gou, Xin |
description | This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes.
We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model.
The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (>4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (
= 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (
= 0.003 and
= 0.002, respectively) and OS (
= 0.016 and
= 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;
= 0.005] and ACCI score >4 (HR, 2.329; 95% CI, 1.105-4.908;
= 0.026) remained independent risk factors for PFS and OS, respectively.
Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx. |
doi_str_mv | 10.3389/fsurg.2023.1121357 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_3329f76daca345b897b0b5620d35ebd8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_3329f76daca345b897b0b5620d35ebd8</doaj_id><sourcerecordid>2799175195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</originalsourceid><addsrcrecordid>eNpVkstu1DAUhiMEolXpC7BAWbLJ1Jf4xgZVFdBKlVhQJHaWb0ldOXGwnUHzBLw2ns5Qtatj-_znOz723zTvIdhgzMXFkNc0bhBAeAMhgpiwV80pQoJ2nJFfr5-tT5rznB8AABD3kKL-bXOCGcCEMHja_P2xpq3fqtAuyVlvio9zq6Y4j-2iyn0McfSmvetbHZS1LrVGzaaGmvRuLrkdYgjxj696syuxMtbK2Lq6y8WZEqfdp_ayTa6kmBd3yOUqD64zFVBRuax29655M6iQ3fkxnjU_v365u7rubr9_u7m6vO1MT0XpDHaA9oBQpDimBgkCFScCIgABt5hr4RyFZNB1cNuznlpqle45U8ogajU-a24OXBvVg1ySn1Tayai8fDyIaZQqFW-CkxgjMbBabxTuieaCaaBrZ2Axcdryyvp8YC2rnpzdj5NUeAF9mZn9vRzjVkIAGMGAVsLHIyHF36vLRU4-GxeCml1cs0RMCMgIFKRK0UFq6kPm5IanPhDIvSPkoyPk3hHy6Iha9OH5DZ9K_v8__gdhTbcM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2799175195</pqid></control><display><type>article</type><title>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</title><source>Open Access: PubMed Central</source><creator>Bai, Xuesong ; Chen, Guo ; Shang, Shihai ; Li, Senlin ; Liu, Huanrui ; Feng, Zhenwei ; Gou, Xin</creator><creatorcontrib>Bai, Xuesong ; Chen, Guo ; Shang, Shihai ; Li, Senlin ; Liu, Huanrui ; Feng, Zhenwei ; Gou, Xin</creatorcontrib><description>This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes.
We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model.
The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (>4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (
= 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (
= 0.003 and
= 0.002, respectively) and OS (
= 0.016 and
= 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;
= 0.005] and ACCI score >4 (HR, 2.329; 95% CI, 1.105-4.908;
= 0.026) remained independent risk factors for PFS and OS, respectively.
Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx.</description><identifier>ISSN: 2296-875X</identifier><identifier>EISSN: 2296-875X</identifier><identifier>DOI: 10.3389/fsurg.2023.1121357</identifier><identifier>PMID: 37035571</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>age-adjusted charlson comorbidity index ; bladder cancer ; cystectomy ; prognosis ; pT4 ; Surgery</subject><ispartof>Frontiers in surgery, 2023-03, Vol.10, p.1121357-1121357</ispartof><rights>2023 Bai, Chen, Shang, Li, Liu, Feng and Gou.</rights><rights>2023 Bai, Chen, Shang, Li, Liu, Feng and Gou. 2023 Bai, Chen, Shang, Li, Liu, Feng and Gou</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</citedby><cites>FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075306/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075306/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37035571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bai, Xuesong</creatorcontrib><creatorcontrib>Chen, Guo</creatorcontrib><creatorcontrib>Shang, Shihai</creatorcontrib><creatorcontrib>Li, Senlin</creatorcontrib><creatorcontrib>Liu, Huanrui</creatorcontrib><creatorcontrib>Feng, Zhenwei</creatorcontrib><creatorcontrib>Gou, Xin</creatorcontrib><title>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</title><title>Frontiers in surgery</title><addtitle>Front Surg</addtitle><description>This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes.
We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model.
The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (>4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (
= 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (
= 0.003 and
= 0.002, respectively) and OS (
= 0.016 and
= 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;
= 0.005] and ACCI score >4 (HR, 2.329; 95% CI, 1.105-4.908;
= 0.026) remained independent risk factors for PFS and OS, respectively.
Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx.</description><subject>age-adjusted charlson comorbidity index</subject><subject>bladder cancer</subject><subject>cystectomy</subject><subject>prognosis</subject><subject>pT4</subject><subject>Surgery</subject><issn>2296-875X</issn><issn>2296-875X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkstu1DAUhiMEolXpC7BAWbLJ1Jf4xgZVFdBKlVhQJHaWb0ldOXGwnUHzBLw2ns5Qtatj-_znOz723zTvIdhgzMXFkNc0bhBAeAMhgpiwV80pQoJ2nJFfr5-tT5rznB8AABD3kKL-bXOCGcCEMHja_P2xpq3fqtAuyVlvio9zq6Y4j-2iyn0McfSmvetbHZS1LrVGzaaGmvRuLrkdYgjxj696syuxMtbK2Lq6y8WZEqfdp_ayTa6kmBd3yOUqD64zFVBRuax29655M6iQ3fkxnjU_v365u7rubr9_u7m6vO1MT0XpDHaA9oBQpDimBgkCFScCIgABt5hr4RyFZNB1cNuznlpqle45U8ogajU-a24OXBvVg1ySn1Tayai8fDyIaZQqFW-CkxgjMbBabxTuieaCaaBrZ2Axcdryyvp8YC2rnpzdj5NUeAF9mZn9vRzjVkIAGMGAVsLHIyHF36vLRU4-GxeCml1cs0RMCMgIFKRK0UFq6kPm5IanPhDIvSPkoyPk3hHy6Iha9OH5DZ9K_v8__gdhTbcM</recordid><startdate>20230322</startdate><enddate>20230322</enddate><creator>Bai, Xuesong</creator><creator>Chen, Guo</creator><creator>Shang, Shihai</creator><creator>Li, Senlin</creator><creator>Liu, Huanrui</creator><creator>Feng, Zhenwei</creator><creator>Gou, Xin</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230322</creationdate><title>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</title><author>Bai, Xuesong ; Chen, Guo ; Shang, Shihai ; Li, Senlin ; Liu, Huanrui ; Feng, Zhenwei ; Gou, Xin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>age-adjusted charlson comorbidity index</topic><topic>bladder cancer</topic><topic>cystectomy</topic><topic>prognosis</topic><topic>pT4</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bai, Xuesong</creatorcontrib><creatorcontrib>Chen, Guo</creatorcontrib><creatorcontrib>Shang, Shihai</creatorcontrib><creatorcontrib>Li, Senlin</creatorcontrib><creatorcontrib>Liu, Huanrui</creatorcontrib><creatorcontrib>Feng, Zhenwei</creatorcontrib><creatorcontrib>Gou, Xin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bai, Xuesong</au><au>Chen, Guo</au><au>Shang, Shihai</au><au>Li, Senlin</au><au>Liu, Huanrui</au><au>Feng, Zhenwei</au><au>Gou, Xin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study</atitle><jtitle>Frontiers in surgery</jtitle><addtitle>Front Surg</addtitle><date>2023-03-22</date><risdate>2023</risdate><volume>10</volume><spage>1121357</spage><epage>1121357</epage><pages>1121357-1121357</pages><issn>2296-875X</issn><eissn>2296-875X</eissn><abstract>This retrospective study aimed to describe our institutional experience with cytoreductive cystectomy (Cx) in patients with pathological T4 (pT4) bladder cancer (BCa) and to investigate the clinicopathologic factors that can predict patient survival outcomes.
We reviewed the baseline demographics, clinicopathologic features, perioperative complications, and follow-up data of 44 patients who underwent Cx for pT4 BCa at our institution between 2013 and 2021. The Kaplan-Meier curve and the log-rank test were used to analyze progression-free survival (PFS) and overall survival (OS). Univariate and multivariate analyses were performed using the Cox regression model.
The median age of the patients was 68 years [95% confidence interval (CI) 49-81]. Overall, 21 patients (47.7%) were estimated to have a high age-adjusted Charlson comorbidity index (ACCI) score (>4), and nine patients (20.5%) had pT4b substage BCa. None of the patients died of complications within 30-90 days after surgery. Severe complications occurred in 16% (
= 7) of patients within 30-90 days. During a median follow-up of 51 months, disease progression was detected in 25 patients (56.8%), and 29 patients (65.9%) died of any cause. The median PFS and OS were 15.0 and 21.0 months, respectively. The Kaplan-Meier analysis indicated that patients with high ACCI scores or pT4b BCa had worse PFS (
= 0.003 and
= 0.002, respectively) and OS (
= 0.016 and
= 0.034, respectively) than those with low ACCI scores or pT4a BCa. On multivariate analysis, pT4b substage [hazard ratio (HR), 4.166; 95% CI, 1.549-11.206;
= 0.005] and ACCI score >4 (HR, 2.329; 95% CI, 1.105-4.908;
= 0.026) remained independent risk factors for PFS and OS, respectively.
Our study revealed that the pT4b substage is associated with a poor prognosis and that the ACCI score is a relevant and practical method to evaluate survival outcomes in patients with pT4 BCa after Cx.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>37035571</pmid><doi>10.3389/fsurg.2023.1121357</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2296-875X |
ispartof | Frontiers in surgery, 2023-03, Vol.10, p.1121357-1121357 |
issn | 2296-875X 2296-875X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_3329f76daca345b897b0b5620d35ebd8 |
source | Open Access: PubMed Central |
subjects | age-adjusted charlson comorbidity index bladder cancer cystectomy prognosis pT4 Surgery |
title | Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A07%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20prediction%20among%20pathologic%20T4%20bladder%20cancer%20patients%20following%20cytoreductive%20cystectomy:%20A%20retrospective%20single-center%20study&rft.jtitle=Frontiers%20in%20surgery&rft.au=Bai,%20Xuesong&rft.date=2023-03-22&rft.volume=10&rft.spage=1121357&rft.epage=1121357&rft.pages=1121357-1121357&rft.issn=2296-875X&rft.eissn=2296-875X&rft_id=info:doi/10.3389/fsurg.2023.1121357&rft_dat=%3Cproquest_doaj_%3E2799175195%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-c3e0640562a836c2951a859120108d38b9ee615fb875d4746d6dab487aac26db3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2799175195&rft_id=info:pmid/37035571&rfr_iscdi=true |